Brief: Arcus Provides Update On Phase 3 STAR-221 Study And Concentrates Its Research And Development Investment On Casdatifan And Emerging Inflammation And Immunology Portfolio
12/12/2025 13:39
Dec 12 (Reuters) - Arcus Biosciences Inc RCUS.N: ARCUS PROVIDES UPDATE ON PHASE 3 STAR-221 STUDY AND CONCENTRATES ITS RESEARCH AND DEVELOPMENT INVESTMENT ON CASDATIFAN AND EMERGING INFLAMMATION AND IMMUNOLOGY PORTFOLIO ARCUS BIOSCIENCES INC: STAR-221 AND PHASE 2 EDGE-GASTRIC STUDIES WILL BE DISCONTINUED ARCUS BIOSCIENCES INC - CONTINUES TO EXPAND CASDATIFAN PROGRAM WITH DATA READOUTS IN 2026 Source text: ID:nBw1ppr59a Further company coverage: RCUS.N ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Arcus Biosciences
See all newsU.S. STOCKS ON THE MOVE-Quest Diagnostics, Tractor Supply, Dutch Bros
U.S. STOCKS ON THE MOVE-CME, Lockheed Martin, Valero Energy
Arcus Biosciences tumbles on $250 mln share sale
Brief: Arcus Biosciences Announces Pricing Of $250 Million Public Offering Of Common Stock
Arcus Biosciences drops after starting stock offering